Free press releases distribution network?

Agency / Source: PRHUB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Cellworks Announces Drug Discovery Collaboration with Orchid Based on Systems Biology Technology - Cellworks Research India Ltd, the R&D wing of CA based company Cellworks Group Inc and the first company in Asia to build Systems Biology based drug discovery solutions has successfully helped Orchid Chemicals & & Pharmaceuticals Ltd. Cellworks
Cellworks Announces Drug Discovery Collaboration with Orchid Based on Systems Biology Technology

 

PRZOOM - /newswire/ - Shantinagar, Karnataka, India, 2008/01/07 - Cellworks Research India Ltd, the R&D wing of CA based company Cellworks Group Inc and the first company in Asia to build Systems Biology based drug discovery solutions has successfully helped Orchid Chemicals & & Pharmaceuticals Ltd. Cellworks.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Orchid Chemicals and Pharmaceuticals Ltd and Cellworks entered into a collaborative agreement in early 2006 with an aim of incorporating new technologies to New Chemical Entity (NCE) research program being initiated by Orchid Chemicals & Pharmaceuticals Ltd. Cellworks with its expertise in Systems Biology leveraged its Inflammation in silico platform comprising of various cell types like Macrophage and T-Cell. The aim behind this project was the identification of mechanism of action of key drugs being used in Industry to treat Inflammation disorders. Getting a clear understanding of the underlying Drug Mechanism and associated toxicities were the driving factors behind this project.

This collaborative research helped in understanding the comprehensive pros and cons of the various drug targets and mechanism. Cellworks technology of automated assertion helped in the identification of the key cellular-level bio-markers in the system for each of the drugs individually and in combination and their corresponding implications. Using Cellworks platform of Systems Biology made it possible to overlay the effect of all the drugs and visualize how a given biological node or an endpoint is affected by the different drugs.

According to Dr.C. Bhaktavatsala Rao, Deputy Managing Director, Orchid Chemicals & Pharmaceuticals Ltd. - “The need to understand the detailed mechanisms of actions, biological targets and associated pros and cons of the landscape of key drugs is essential for a differentiated New Molecule Entity project. We've been closely working with the Cellworks solution for one of our key internal Drug Discovery projects and were able to quickly ascertain which biological receptor target to focus on. We believe that the adoption of the Systems Biology platform from Cellworks will significantly improve our overall Drug discovery methodology. Close collaboration with Cellworks expands our disease biology skills and enables us to deliver better efficacy drugs with contained side-effects to our customers”.

According to Dr. Anandkumar, Chairman Board of Cellworks Research India Ltd – “The collaboration between Orchid Chemicals & Pharmaceuticals Ltd and Cellworks is ongoing in different drug discovery areas pertaining to Inflammation. It’s very exciting to note than an India based company is taking the lead in incorporating bleeding edge ideas into drug discovery related Research and Development. On behalf of Cellworks – we really appreciate this partnership opportunity and look forward to building up this collaborative research in coming years.”

According to Taher Abbasi, CEO of Cellworks – “We are today working with several partner-collaborators and it is gratifying to see that our very first Industrial overture is starting to produce high value results. We are very happy at providing value to Orchid’s Drug discovery program and in the process Cellworks has taken a leadership position in very important but poorly understood areas like disease progression”.

About Orchid Chemicals and Pharmaceuticals
Orchid Chemicals & Pharmaceuticals Ltd a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery. Orchid has been investing aggressively for establishing modern research and manufacturing facilities aimed at global markets, thus emerging as a world-class pharmaceutical company covering the entire value chain from “Discovery to Delivery”.

About Cellworks
Cellworks Group Inc. is a California Incorporated company with its R&D facility (Cellworks Research India Ltd) based in Bangalore, India. Cellworks adopts a multi-disciplinary and analytical approach to solve biological problems and is part of a new technology wave that will change people’s perception of the diagnosis and treatment of human disease.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: PRHUB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cellworks Announces Drug Discovery Collaboration with Orchid Based on Systems Biology Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: PRHub 
+91 80 22483007 tania[.]prhub.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PRHUB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From PRHUB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  RightITnow Ltd

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today